Whitlock Gary, Lewington Sarah, Sherliker Paul, Clarke Robert, Emberson Jonathan, Halsey Jim, Qizilbash Nawab, Collins Rory, Peto Richard
Lancet. 2009 Mar 28;373(9669):1083-96. doi: 10.1016/S0140-6736(09)60318-4. Epub 2009 Mar 18.
The main associations of body-mass index (BMI) with overall and cause-specific mortality can best be assessed by long-term prospective follow-up of large numbers of people. The Prospective Studies Collaboration aimed to investigate these associations by sharing data from many studies.
Collaborative analyses were undertaken of baseline BMI versus mortality in 57 prospective studies with 894 576 participants, mostly in western Europe and North America (61% [n=541 452] male, mean recruitment age 46 [SD 11] years, median recruitment year 1979 [IQR 1975-85], mean BMI 25 [SD 4] kg/m(2)). The analyses were adjusted for age, sex, smoking status, and study. To limit reverse causality, the first 5 years of follow-up were excluded, leaving 66 552 deaths of known cause during a mean of 8 (SD 6) further years of follow-up (mean age at death 67 [SD 10] years): 30 416 vascular; 2070 diabetic, renal or hepatic; 22 592 neoplastic; 3770 respiratory; 7704 other.
In both sexes, mortality was lowest at about 22.5-25 kg/m(2). Above this range, positive associations were recorded for several specific causes and inverse associations for none, the absolute excess risks for higher BMI and smoking were roughly additive, and each 5 kg/m(2) higher BMI was on average associated with about 30% higher overall mortality (hazard ratio per 5 kg/m(2) [HR] 1.29 [95% CI 1.27-1.32]): 40% for vascular mortality (HR 1.41 [1.37-1.45]); 60-120% for diabetic, renal, and hepatic mortality (HRs 2.16 [1.89-2.46], 1.59 [1.27-1.99], and 1.82 [1.59-2.09], respectively); 10% for neoplastic mortality (HR 1.10 [1.06-1.15]); and 20% for respiratory and for all other mortality (HRs 1.20 [1.07-1.34] and 1.20 [1.16-1.25], respectively). Below the range 22.5-25 kg/m(2), BMI was associated inversely with overall mortality, mainly because of strong inverse associations with respiratory disease and lung cancer. These inverse associations were much stronger for smokers than for non-smokers, despite cigarette consumption per smoker varying little with BMI.
Although other anthropometric measures (eg, waist circumference, waist-to-hip ratio) could well add extra information to BMI, and BMI to them, BMI is in itself a strong predictor of overall mortality both above and below the apparent optimum of about 22.5-25 kg/m(2). The progressive excess mortality above this range is due mainly to vascular disease and is probably largely causal. At 30-35 kg/m(2), median survival is reduced by 2-4 years; at 40-45 kg/m(2), it is reduced by 8-10 years (which is comparable with the effects of smoking). The definite excess mortality below 22.5 kg/m(2) is due mainly to smoking-related diseases, and is not fully explained.
体重指数(BMI)与全因死亡率及特定病因死亡率之间的主要关联,最好通过对大量人群进行长期前瞻性随访来评估。前瞻性研究协作组旨在通过共享多项研究的数据来调查这些关联。
对57项前瞻性研究中的894576名参与者的基线BMI与死亡率进行了协作分析,这些研究大多来自西欧和北美(61%[n = 541452]为男性,平均招募年龄46岁[标准差11岁],招募年份中位数为1979年[四分位间距1975 - 1985年],平均BMI为25[标准差4]kg/m²)。分析对年龄、性别、吸烟状况和研究进行了调整。为限制反向因果关系,排除了随访的前5年,在随后平均8年(标准差6年)的随访期间有66552例已知病因死亡(死亡时平均年龄67岁[标准差10岁]):30416例为血管性疾病;2070例为糖尿病、肾脏或肝脏疾病;22592例为肿瘤;3770例为呼吸系统疾病;7704例为其他疾病。
在男性和女性中,BMI约为22.5 - 25kg/m²时死亡率最低。高于此范围,记录到几种特定病因的正相关,未发现负相关,较高BMI和吸烟的绝对超额风险大致相加,BMI每升高5kg/m²,全因死亡率平均约升高30%(每5kg/m²的风险比[HR]为1.29[95%置信区间1.27 - 1.32]):血管性死亡率升高40%(HR 1.41[1.37 - 1.45]);糖尿病、肾脏和肝脏疾病死亡率升高60% - 120%(HR分别为2.16[1.89 - 2.46]、1.59[1.27 - 1.99]和1.82[1.59 - 2.09]);肿瘤死亡率升高10%(HR 1.10[1.06 - 1.15]);呼吸系统疾病和所有其他疾病死亡率升高20%(HR分别为1.20[1.07 - 1.34]和1.20[1.16 - 1.25])。低于22.5 - 25kg/m²范围时,BMI与全因死亡率呈负相关,主要是因为与呼吸系统疾病和肺癌有很强的负相关。尽管每个吸烟者的香烟消费量随BMI变化不大,但这些负相关在吸烟者中比非吸烟者中要强得多。
尽管其他人体测量指标(如腰围、腰臀比)可能会为BMI增添额外信息,反之亦然,但BMI本身就是全因死亡率的有力预测指标,无论高于还是低于约22.5 - 25kg/m²这个明显的最佳范围。高于此范围死亡率的逐步增加主要归因于血管疾病,可能在很大程度上是因果关系。BMI为30 - 35kg/m²时,中位生存期缩短2 - 4年;BMI为40 - 45kg/m²时,中位生存期缩短8 - 10年(这与吸烟的影响相当)。低于22.5kg/m²时明确的超额死亡率主要归因于与吸烟相关的疾病,且尚未得到充分解释。